Table 3 Summary of the endocrine-related immune-related adverse events (irAE) frequency associated with immune checkpoint inhibitors (ICI) in various carcinomas (modified from refs. 3, 4)
Drug name | Frequency of endocrine-related irAEs (%) | ||||
|---|---|---|---|---|---|
Pituitary disorder | Hypothyroidism | Adrenal insufficiency | Type 1 diabetes | ||
Anti PD-L1 | Nivolumab | 0 ~ 0.9 | 10 | 0 ~ 3.3 | 0.25 |
Pembrolizumab | 0 ~ 1.2 | 10 ~ 20 | 0 ~ 4.3 | Case reports exist | |